We bring together the forces behind advanced therapies
ATMP Denmark is a national collaborative structure designed to strengthen the development, testing and use of advanced therapy medicinal products. We bring together hospitals, academic and research environments, authorities and industry in a single point of entry for knowledge, guidance and collaboration.
That’s why ATMP Denmark exists
Advanced therapies offer new opportunities to treat both rare diseases and some of the major common diseases for which there is currently no effective treatment. But the path from research to treatment is complex. Compared with traditional medicines, advanced therapies place particular demands on both clinical trials and the conditions surrounding the clinical implementation itself, which requires close collaboration across many stakeholders.
That is why ATMP Denmark exists.
We work to strengthen the Danish ecosystem for advanced therapies through better coordination, collaboration and knowledge sharing across research, clinical practice, authorities and industry.
At the same time, we work to position Denmark as an attractive and competitive environment for the development, testing, production and implementation of advanced therapies.
This is how we are organized
ATMP Danmark is organized with a steering committee, a broadly composed reference group, and an independent secretariat that drives and coordinates the day-to-day work. The steering committee can establish time-limited working groups when there is a need for specialized knowledge.
Political support
ATMP Danmark is based on national, political strategies and was established by Ministry of Health and Ecclesiastical Affairs of Denmark, Danish Regions, and Amgros as an association. ATMP Danmark is funded with a total of DKK 28.5 million through the Strategy for life science towards 2030 and the Personalised medicine strategy 2025 - 2027.
Read the strategies here:
Strategy for life science towards 2030
&
Personalised medicine strategy 2025 - 2027
Denmark should be a leading country in the development and implementation of ATMP by strengthening the framework conditions for clinical research to attract more clinical trials to Denmark, support the transition from research to treatment, and make it more attractive to market ATMPs in Denmark.
Drive projects and initiatives
The secretariat plans and follows up on activities, ensures progress, and turns knowledge into concrete deliverables.
Sets the strategic direction
The steering committee sets the strategic direction, prioritizes initiatives, and closely monitors progress.
Dorte Bech Vizard - chairmanship
Head of Department, Ministry of Health and Ecclesiastical Affairs of Denmark
Erik Jylling - chairmanship
Chief Executive Officer, The Capital Region of Denmark
Flemming Sonne
Chief Executive Officer, Amgros
Birgitte Klindt Poulsen
Chair, Danish Medicines Council
Charlotte Birkmose Rotbøl
Medical Director, Aarhus University Hospital
Emilie Sophie Frank
Team Lead, Danish Regions
Trine Winterø
Prodekan, University of Copenhagen
Søren Pihlkjær Hjortshøj
Medical Director, Aalborg University Hospital
Henrik Frederiksen
Chair, Danish Comprehensive Cancer Center
Flemming Konradsen
Chief Scientific Officer, Novo Nordisk Foundation
Michael Dall
Medical Director, Odense University Hospital
Jan-Wilhelm Kornfeld
Professor, University of Southern Denmark
Camilla Lund-Cramer
Health Policy Director, The Danish Association of the Pharmaceutical Industry
Nanna Aaby Thirstrup
Head of Unit, Danish Medicines Agency
Materials from steering committee meetings in 2026
Here you will find agendas and minutes from ATMP Denmark’s steering group meetings. The material provides insight into decisions, discussions, and progress in the work.
Materials from steering committee meetings in 2025
Here you will find agendas and minutes from ATMP Denmark’s first year. Dive into decisions, discussions, and the start of the work.
A strong link between knowledge and practice
The reference group contributes professional perspectives to analyses and deliverables. It represents the ecosystem, acts as a link, and helps ensure that the work stays close to practice, and that new knowledge is shared and put into action. See the members of the reference group. Some members represent an organization – for example, Danish Patients and the Danish universities.
Trial Nation
The Danish Medicines Agency
Aarhus University Hospital
The Danish Association of the Pharmaceutical Industry
Danish Regions
Amgros
The Danish Health Authority
Aalborg University Hospital
The Danish Medicines Council
Danish Society for Clinical Immunology (DSKI)
Zealand University Hospital
Danish Comprehensive Cancer Center
Herlev Hospital
Odense University Hospital
Material from reference group meetings in 2026
Here you will find agendas and minutes from reference group meetings, as well as an overview of members and their organizations.
Organization after 2027
ATMP Denmark is working to establish a single coordinated point of entry by the end of 2027.
Denmark must stand strong in the development and use of advanced therapies. This requires an organization that brings research, development, and clinical practice closer together—and that creates a sustainable framework for the ATMP area after 2027.
The organization must support:
Close interaction between research, development, and clinical implementation
Clear frameworks, strong collaborations, and sustainable structures
Long-term anchoring that strengthens Denmark's position within advanced therapies
Innovative treatments benefiting patients at a high professional level
